|Description||Alofanib, also known as RPT835, is a potent and selective allosteric inhibitor of FGFR2 with potential anticancer activity. Alofanib blocks the extracellular part of the receptor and prevents its binding with the ligand.|
|B0084-470877||10 mg||$899||In stock|
|Solubility||Soluble in DMSO, not in water|
|Shelf Life||2 years|
This active molecular is a Axl receptor tyrosine kinase inhibitor, Proto oncogene protein c met inhibitor, Type-1, Type-2 and Type-3 fibroblast growth factor re...
SU11652 is a cell-permeable and sunitinib-like inhibitor of tyrosine kinase receptor (RTK) and angiogenesis with antineoplastic property. It selectively inhibit...
ACTB-1003 is an oral kinase inhibitor with multiple modes of action, targeting cancer mutations via FGFR inhibition FGFR1, angiogenesis through inhibition of VE...
ARQ-087, also known as Derazantinib, is an oral fibroblast growth factor receptor (FGFR) inhibitor with antitumor property. FGFR plays a role in the regulation ...
SKLB610 is a VEGFR inhibitor that potently suppresses human tumor angiogenesis. SKLB610 inhibited angiogenesis-related tyrosine kinase VEGFR2, fibroblast growth...
NSC12 is an extracellular trap for fibroblast growth factor 2 (FGF2). It binds FGF2 with Kd value of 51 µM and interferes with its interaction with FGFR1 withou...
FGFR4-IN-1 is a potent and selective FGFR4 inhibitor with potential for the treatment of gastric cancer.
Debio-1347, also known as FF284 and CH5183284, is an orally bioavailable inhibitor of the fibroblast growth factor receptor subtypes 1 (FGFR-1), 2 (FGFR-2) and ...